X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs DR. REDDYS LAB - Comparison Results

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA DR. REDDYS LAB AJANTA PHARMA/
DR. REDDYS LAB
 
P/E (TTM) x 24.9 29.9 83.4% View Chart
P/BV x 10.3 2.9 350.7% View Chart
Dividend Yield % 0.6 0.9 63.3%  

Financials

 AJANTA PHARMA   DR. REDDYS LAB
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
DR. REDDYS LAB
Mar-17
AJANTA PHARMA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1,7203,397 50.6%   
Low Rs1,1032,560 43.1%   
Sales per share (Unadj.) Rs194.6856.5 22.7%  
Earnings per share (Unadj.) Rs45.278.0 58.0%  
Cash flow per share (Unadj.) Rs50.3139.9 36.0%  
Dividends per share (Unadj.) Rs8.0020.00 40.0%  
Dividend yield (eoy) %0.60.7 84.4%  
Book value per share (Unadj.) Rs132.0739.8 17.8%  
Shares outstanding (eoy) m88.77165.74 53.6%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x7.33.5 208.6%   
Avg P/E ratio x31.238.2 81.7%  
P/CF ratio (eoy) x28.121.3 131.8%  
Price / Book Value ratio x10.74.0 265.6%  
Dividend payout %17.725.7 69.0%   
Avg Mkt Cap Rs m125,299493,632 25.4%   
No. of employees `000NA22.7 0.0%   
Total wages/salary Rs m2,57031,068 8.3%   
Avg. sales/employee Rs ThNM6,259.0-  
Avg. wages/employee Rs ThNM1,369.8-  
Avg. net profit/employee Rs ThNM569.7-  
INCOME DATA
Net Sales Rs m17,275141,961 12.2%  
Other income Rs m1661,715 9.7%   
Total revenues Rs m17,442143,676 12.1%   
Gross profit Rs m5,80724,722 23.5%  
Depreciation Rs m45110,266 4.4%   
Interest Rs m49634 7.7%   
Profit before tax Rs m5,47415,537 35.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m0349 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,4602,965 49.2%   
Profit after tax Rs m4,01412,921 31.1%  
Gross profit margin %33.617.4 193.0%  
Effective tax rate %26.719.1 139.8%   
Net profit margin %23.29.1 255.3%  
BALANCE SHEET DATA
Current assets Rs m7,63996,837 7.9%   
Current liabilities Rs m2,71584,199 3.2%   
Net working cap to sales %28.58.9 320.2%  
Current ratio x2.81.2 244.7%  
Inventory Days Days4373 58.9%  
Debtors Days Days7998 80.6%  
Net fixed assets Rs m6,914102,552 6.7%   
Share capital Rs m177829 21.3%   
"Free" reserves Rs m11,442121,792 9.4%   
Net worth Rs m11,721122,621 9.6%   
Long term debt Rs m1495,449 2.7%   
Total assets Rs m14,814218,165 6.8%  
Interest coverage x112.925.5 442.8%   
Debt to equity ratio x00 28.6%  
Sales to assets ratio x1.20.7 179.2%   
Return on assets %27.46.2 441.4%  
Return on equity %34.210.5 325.0%  
Return on capital %46.512.9 360.7%  
Exports to sales %55.154.6 101.0%   
Imports to sales %6.09.4 64.2%   
Exports (fob) Rs m9,52777,520 12.3%   
Imports (cif) Rs m1,03813,274 7.8%   
Fx inflow Rs m10,42281,670 12.8%   
Fx outflow Rs m1,67826,355 6.4%   
Net fx Rs m8,74455,315 15.8%   
CASH FLOW
From Operations Rs m3,26421,444 15.2%  
From Investments Rs m-2,093-18,404 11.4%  
From Financial Activity Rs m-1,186-3,692 32.1%  
Net Cashflow Rs m-15-1,144 1.3%  

Share Holding

Indian Promoters % 73.8 25.5 289.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 5.4 28.7%  
FIIs % 7.6 35.3 21.5%  
ADR/GDR % 0.0 18.5 -  
Free float % 17.0 15.3 111.1%  
Shareholders   20,968 75,885 27.6%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  CADILA HEALTHCARE  NOVARTIS  DR. DATSONS LABS  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Feb 23, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS